Harrison CN et al. Expand: A Phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 x 10⁹/L and 99 x 10⁹/L. Proc ASH 2012;Abstract 177.

Dr Talpaz is Alexander J Trotman Professor of Leukemia Research, Associate Director of Translational Research at UM Comprehensive Cancer Center, Associate Chief of the Division of Hematology/Oncology and Director of Hematologic Malignancies at the University of Michigan Medical Center in Ann Arbor, Michigan.